Sodelglitazar

Chemical compound
  • N/A
ATC code
  • None
Legal statusLegal status
  • Investigational
Identifiers
  • [4-[[[2-[2-Fluoro-4-(trifluoromethyl)phenyl]-4-methyl-1,3-thiazol-5-yl]methyl]sulfanyl]-2-methylphenoxy]-2-methylpropanoic acid[1]
CAS Number
  • 447406-78-2
PubChem CID
  • 9805950
ChemSpider
  • 7981710
UNII
  • 6G973E04VI
KEGG
  • D06647
ChEMBL
  • ChEMBL2104984
CompTox Dashboard (EPA)
  • DTXSID90196289 Edit this at Wikidata
Chemical and physical dataFormulaC23H21F4NO3S2Molar mass499.54 g·mol−13D model (JSmol)
  • Interactive image
  • CC1=C(C=CC(=C1)SCC2=C(N=C(S2)C3=C(C=C(C=C3)C(F)(F)F)F)C)OC(C)(C)C(=O)O
InChI
  • InChI=1S/C23H21F4NO3S2/c1-12-9-15(6-8-18(12)31-22(3,4)21(29)30)32-11-19-13(2)28-20(33-19)16-7-5-14(10-17(16)24)23(25,26)27/h5-10H,11H2,1-4H3,(H,29,30)
  • Key:ZUGQWAYOWCBWGM-UHFFFAOYSA-N

Sodelglitazar, formerly known as GW 677954, is a thiazole PPARδ receptor agonist developed by GlaxoSmithKline.[2] While it is primarily active at the PPARδ receptor, it is considered a pan agonist with activity at PPARα and PPARγ receptors.[3]

Safety

Phase 2 studies were terminated prior to completion due to safety findings in rodent studies.[4]

See also

References

  1. ^ US abandoned 7105551, Rodolfo C, Marie GR, Hurst III LM, Lawrence SM, "Thiazole derivatives for treating ppar related disorders", published 1 April 2004, assigned to SmithKlineBeecham 
  2. ^ Liu XY, Wang RL, Xu WR, Tang LD, Wang SQ, Chou KC (October 2011). "Docking and molecular dynamics simulations of peroxisome proliferator activated receptors interacting with pan agonist sodelglitazar". Protein and Peptide Letters. 18 (10): 1021–7. doi:10.2174/092986611796378701. PMID 21592078.
  3. ^ Ottow E, Weinmann H (2008). Nuclear Receptors as Drug Targets. Wiley. pp. 380–. ISBN 978-3-527-31872-8. Retrieved 2 April 2013.
  4. ^ "A randomised, double-blind, parallel group, placebo-controlled, multicentre study to evaluate the safety, tolerability and efficacy of oral GW677954 capsules 2.5mg, 5mg, 10mg and 20mg a day for 24 weeks in overweight dyslipidaemic subjects" (PDF). GlaxoSmithKline. 2013-09-01. Archived from the original (PDF) on 6 March 2017.
  • v
  • t
  • e
PPARTooltip Peroxisome proliferator-activated receptor modulators
PPARαTooltip Peroxisome proliferator-activated receptor alphaPPARδTooltip Peroxisome proliferator-activated receptor delta
  • Antagonists: FH-535
  • GSK-0660
  • GSK-3787
PPARγTooltip Peroxisome proliferator-activated receptor gamma
  • SPPARMsTooltip Selective PPARγ modulator: BADGE
  • EPI-001
  • INT-131
  • MK-0533
  • S26948
  • Antagonists: FH-535
  • GW-9662
  • SR-202
  • T-0070907
  • Unknown: SR-1664
Non-selective
See also
Receptor/signaling modulators


Stub icon

This pharmacology-related article is a stub. You can help Wikipedia by expanding it.

  • v
  • t
  • e